Active, not recruitingPHASE1, PHASE2NCT05089370
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
Studying Malignant melanoma of the mucosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Colorado, Denver
- Principal Investigator
- Martin McCarter, MDColorado Research Center
- Intervention
- Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab(combination_product)
- Enrollment
- 8 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2022 – 2026
Study locations (1)
- University of Colorado Hospital, Aurora, Colorado, United States
Collaborators
National Comprehensive Cancer Network · Taiho Oncology, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05089370 on ClinicalTrials.govOther trials for Malignant melanoma of the mucosa
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06797297A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyInnovent Biologics (Suzhou) Co. Ltd.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05661955A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.BeiGene
- RECRUITINGPHASE2NCT04879654Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic SurgeryEye & ENT Hospital of Fudan University